Companies · Biotechnology

Kona Medical, Inc.

PALO ALTO · Biotechnology

Diligence memoA one-page analyst read on Kona Medical, Inc. — recommendation, valuation, rhythm, risks.
$61.6M
Total raised · real
6
Rounds
0.3×
Latest step-up
Top 16%
Sector rank · raised
Series B
Latest stage · inferred · Thu Aug 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Kona Medical, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.55× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era.
Dormant
  • Last raise 10.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Kona Medical, Inc. is one of 4293 Biotechnology companies tracked from PALO ALTO. By capital raised it ranks in the upper tier (ahead of 85% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BPre-Seed · 2010-04-02 Raised $200K (real) Modeled valuation $11M (est)$200K$11MPre-Seed2010Seed · 2010-06-17 Raised $2.6M (real) Modeled valuation $115M (est)$2.6M$115MSeed2010Series A · 2011-01-18 Raised $11M (real) Modeled valuation $392M (est)$11M$392MSeries A2011Series A · 2011-01-18 Raised $8.0M (real) Modeled valuation $288M (est)$8.0M$288MSeries A2011Series B · 2012-05-25 Raised $30M (real) Modeled valuation $1.2B (est)$30M$1.2BSeries B2012Series B · 2015-08-20 Raised $10M (real) Modeled valuation $397M (est)$10M$397MSeries B2015+$2.6M+$11M+$8.0M+$30M+$10MCumulative $62M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$200K · 2010
Seed$2.6M · 2010
Series A$10.9M · 2011
Series A extension$8.0M · 2011
Series B$30.0M · 2012
Series B extension$10.0M · 2015

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$396.9M
Base estimate est.
$20.0M
Conservative case
$1.5B
Upside case
$55.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $11.0M · 2010-04-022010Seed · modeled $115.5M · 2010-06-17Series A · modeled $392.5M · 2011-01-18Series A · modeled $287.6M · 2011-01-18Series B · modeled $1.2B · 2012-05-25Series B · modeled $396.9M · 2015-08-202015
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
10.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$11.4M/yr
Capital velocity
16.3 yr
On record since
2010
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.6× above median
This company$61.6M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.6× of median
This company$10.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 6.2× above median
This company$396.9M
Sector median$64.2M

Raised more than 85% of sector peers (real $). Modeled value above 81% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #53 of 77.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)BioAtla,LLC · Series B Raised $47.9M · modeled $1.5B (est)Scholar Rock LLC · Series B Raised $36.3M · modeled $1.4B (est)Oligasis, LLC · Series B Raised $35.8M · modeled $1.3B (est)Alector LLC · Series B Raised $32.3M · modeled $1.3B (est)Gelesis Inc · Series B Raised $37.7M · modeled $1.3B (est)Prosetta Biosciences Inc. · Series B Raised $31.1M · modeled $1.2B (est)Stem Cell Therapeutics Corp · Series B Raised $30.3M · modeled $1.2B (est)Tenex Health, Inc. · Series B Raised $57.4M · modeled $1.2B (est)Aquesys Inc · Series B Raised $49.5M · modeled $1.2B (est)4Tech, Inc. · Series B Raised $62.3M · modeled $1.1B (est)Lorus Therapeutics Inc · Series B Raised $28.3M · modeled $1.1B (est)Kallyope, Inc. · Series B Raised $28.1M · modeled $1.1B (est)Kona Medical, Inc. (this company) Raised $61.6M · modeled $396.9M (est)Kona Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
BioAtla,LLCSeries B$47.9M$1.5B2.16×
Scholar Rock LLCSeries B$36.3M$1.4B2.01×
Oligasis, LLCSeries B$35.8M$1.3B1.88×
Alector LLCSeries B$32.3M$1.3B1.79×
Gelesis IncSeries B$37.7M$1.3B1.75×
Prosetta Biosciences Inc.Series B$31.1M$1.2B1.73×
Stem Cell Therapeutics CorpSeries B$30.3M$1.2B1.68×
Tenex Health, Inc.Series B$57.4M$1.2B1.66×
Aquesys IncSeries B$49.5M$1.2B1.66×
4Tech, Inc.Series B$62.3M$1.1B1.60×
Lorus Therapeutics IncSeries B$28.3M$1.1B1.57×
Kallyope, Inc.Series B$28.1M$1.1B1.56×
Kona Medical, Inc. this companySeries B$61.6M$396.9M0.55×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$200K2010-04-02$1.1M$11.0M90%
Seed$2.6M2010-06-17$13.0M$115.5M90%
Series A$10.9M2011-01-18$49.4M$392.5M90%
Series A$8.0M2011-01-18$36.2M$287.6M90%
Series B$30.0M2012-05-25$166.7M$1.2B90%
Series B$10.0M2015-08-20$55.6M$396.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$200K2010-04-02
    • First recorded raise — entered as Pre-Seed.
  2. Seed$2.6M2010-06-17
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 13.0× larger than the prior — scaling up.
  3. Series A$10.9M2011-01-18
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 4.2× larger than the prior — scaling up.
  4. Series A$8.0M2011-01-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× smaller than the prior — bridge or down round.
  5. Series B$30.0M2012-05-25
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
  6. Series B$10.0M2015-08-20
    • Raised again after 39 mo — slower than the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
Intelligence
2016 ~Q3
Modeled next raise · ~13mo cadence
$10.0M
Modeled next size est.range $10.0M$16.0M
0.3×
Last step-up
$11.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Brian Halak9 other2010-06
Peter Cohn9 other2010-04
Henry A. Plain, Jr.6 other2015-08
Immanuel Thangaraj5 other2010-06
Hank Plain4 other2011-01
Christopher A. Shen2 other2015-08
Louis Cannon2 other2010-06
Michael Gertner1 other2010-04
Registry & provenance

Kona Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1490581
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Oraya Therapeutics IncOther TechnologySeries B$74.9M$765.4Mnetwork3 shared operators · same stage
WindMIL Therapeutics, Inc.BiotechnologySeries B$44.9M$72.5Mnetwork1 shared operator · same sector · same stage
SonoThera, Inc.BiotechnologySeries B$30.4M$550.9Mnetwork1 shared operator · same sector · same stage
TWELVE, Inc.Other TechnologySeries B$88.8M$1.1Bnetwork2 shared operators · same stage
Fortress Biotech, Inc.BiotechnologySeries B$61.9M$258.7Msame sector · same stage
Cell Biosciences IncBiotechnologySeries B$62.3M$516.0Msame sector · same stage
Senseonics, IncBiotechnologySeries B$60.8M$396.9Msame sector · same stage
Vita Therapeutics, Inc.BiotechnologySeries B$62.9M$461.5Msame sector · same stage
Frequently asked
How much funding has Kona Medical, Inc. raised?
Kona Medical, Inc. has raised approximately $61.6M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Kona Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Kona Medical, Inc. is approximately $396.9M (modeled range $20.0M–$1.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kona Medical, Inc. at?
Kona Medical, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Aug 20.
What does Kona Medical, Inc. do and where is it based?
Kona Medical, Inc. operates in the Biotechnology sector, based in PALO ALTO.
Explore related

See where Kona Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kona Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.